94E.F (FSX) is a cross-listing of ZURA (NASDAQ). Showing primary listing data.
ZURA
Zura Bio Limited
1W: -6.2%
1M: -16.0%
3M: +29.2%
YTD: +1.3%
1Y: +316.3%
$6.04
+0.42 (+7.47%)
After Hours: $5.89 (-0.15, -2.40%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$31.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$365.4M
52W Range0.97-7.44
Volume749,206
Avg Volume687,020
Beta0.18
Dividend—
Analyst Ratings
Company Info
CEOSandeep C. Kulkarni
Employees30
SectorHealthcare
IndustryBiotechnology
IPO Date2023-03-21
Websitezurabio.com
4225 Executive Square
San Diego, CA 92037
US
San Diego, CA 92037
US
858 247 0520
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Latest News
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA
12 Health Care Stocks Moving In Monday's After-Market Session
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Zura Bio prices $125M public offering
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AI Biotechnology LLC | P-Purchase | 2,000,000 | $6.25 | 2026-02-26 |
| Nirula Ajay | A-Award | 37,812 | $6.53 | 2026-02-21 |
| Nirula Ajay | 0 | — | 2026-02-21 | |
| Eisner Mark | A-Award | 37,812 | $6.53 | 2026-02-21 |
| Eisner Mark | 0 | — | 2026-02-21 |